The earnings call reflected a strong performance for Ascendis Pharma with significant revenue growth, successful product launches, and strategic progress in their pipeline. While there are challenges related to currency impacts and patient conversion timelines, these are offset by the momentum in product adoption and regulatory advancements.

Company Guidance

During the Q2 2025 earnings call for Ascendis Pharma, the company provided several financial and strategic updates. Revenue for the second quarter reached EUR 153.7 million, with YORVIPATH contributing EUR 103 million, more than doubling from Q1 despite currency headwinds. SKYTROFA generated EUR 50.7 million in revenue, with a negative currency impact of EUR 1.8 million. The company highlighted the strong launch of YORVIPATH, with over 3,100 unique patients receiving prescriptions from more than 1,500 prescribers in the U.S. and noted high payer approval rates within three months. Ascendis expects YORVIPATH to become a blockbuster product, with plans to expand its market presence and leverage strategic partnerships. Additionally, Ascendis reported a decrease in R&D expenses to EUR 72 million and an increase in SG&A expenses to EUR 107.6 million, driven by global commercial expansion. The company ended the quarter with cash and cash equivalents totaling EUR 494 million, expecting to become cash flow positive on a quarterly basis this year.

Strong Revenue Growth for YORVIPATH

YORVIPATH revenue in Q2 reached EUR 103 million, more than double from Q1 2025, with strong U.S. uptake and continued international growth.

FDA Approval and Expansion for SKYTROFA

SKYTROFA received FDA approval for adult growth hormone deficiency, with Q2 revenue of EUR 51 million, and plans for further label expansion.

Priority Review for TransCon CNP

FDA granted priority review for TransCon CNP with a PDUFA date of November 30, recognizing its potential to significantly improve treatment for achondroplasia.

Progress in Combination Therapy for Achondroplasia

Interim Phase II results showed a boost in linear growth and body proportionality improvement in achondroplasia patients using a combination of TransCon CNP and TransCon Growth Hormone.

Strong Financial Position

Total Q2 product revenue was EUR 153.7 million, with expectations for Ascendis to become cash flow positive on a quarterly basis this year.

Ascendis Pharma (ASND) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ASND Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.31 / -	-2.012	―	―	―
Aug 07, 2025	2025 (Q2)	-1.50 / -0.96	-2.234	57.07% (+1.27)	―
May 01, 2025	2025 (Q1)	-1.72 / -1.85	-2.69	31.30% (+0.84)	―
Feb 12, 2025	2024 (Q4)	-1.15 / -0.75	-1.801	58.44% (+1.05)	―
Nov 14, 2024	2024 (Q3)	-1.83 / -2.01	-3.146	36.06% (+1.13)	―
Sep 03, 2024	2024 (Q2)	-1.71 / -2.23	-2.526	11.57% (+0.29)	―
May 02, 2024	2024 (Q1)	-1.73 / -2.69	-2.316	-16.16% (-0.37)	―
Feb 07, 2024	2023 (Q4)	-2.12 / -1.80	-4.328	58.38% (+2.53)	―
Nov 07, 2023	2023 (Q3)	-2.78 / -3.15	-3.632	13.37% (+0.49)	―
Sep 05, 2023	2023 (Q2)	-2.95 / -2.53	-1.708	-47.95% (-0.82)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ASND Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$190.35	$191.49	+0.60%
May 01, 2025	$167.47	$172.06	+2.74%
Feb 12, 2025	$126.14	$142.49	+12.96%
Nov 14, 2024	$124.28	$126.51	+1.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ascendis Pharma A/S (ASND) report earnings?

Ascendis Pharma A/S (ASND) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Ascendis Pharma A/S (ASND) earnings time?

Ascendis Pharma A/S (ASND) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ASND EPS forecast?

ASND EPS forecast for the fiscal quarter 2025 (Q3) is -0.31.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing